昆明医科大学学报
昆明醫科大學學報
곤명의과대학학보
Journal of Kunming Medical University
2014年
2期
15-17
,共3页
鲁一兵%戴海龙%光雪峰%张伟华%薛强%邓洁
魯一兵%戴海龍%光雪峰%張偉華%薛彊%鄧潔
로일병%대해룡%광설봉%장위화%설강%산길
波生坦%先天性心脏病%肺动脉高压
波生坦%先天性心髒病%肺動脈高壓
파생탄%선천성심장병%폐동맥고압
Bosentan%Vongenital heart disease%Pulmonary arterid hypertension
目的:观察波生坦治疗先心病合并重度肺动脉高压的临床疗效.方法5例先心病合并重度肺动脉高压患者服用波生坦治疗,观察服药6月后肺动脉压、肺血管阻力、6 min步行试验、右室收缩末期内径变化情况并进行统计学分析.结果服用波生坦后(1)肺动脉收缩压从(96±11) mmHg降为(86±10) mmHg (<0.01),肺动脉舒张压(56±10) mmHg降为(46±9) mmHg (<0.01).肺动脉平均压(73±11) mmHg降为(59±10) mmHg (<0.05).肺血管阻力(17.8±1.9) Wood降为(13.1±1.7) Wood (<0.01);(2)6 min步行试验从(136±40) m改善为(198±55) m (<0.01);(3)右室收缩末期内径从(40±5) mm减为(36±6) mm (<0.05).结论波生坦可降低先心病合并重度肺动脉高压患者的肺动脉压,提高患者的运动耐量,改善右室功能.
目的:觀察波生坦治療先心病閤併重度肺動脈高壓的臨床療效.方法5例先心病閤併重度肺動脈高壓患者服用波生坦治療,觀察服藥6月後肺動脈壓、肺血管阻力、6 min步行試驗、右室收縮末期內徑變化情況併進行統計學分析.結果服用波生坦後(1)肺動脈收縮壓從(96±11) mmHg降為(86±10) mmHg (<0.01),肺動脈舒張壓(56±10) mmHg降為(46±9) mmHg (<0.01).肺動脈平均壓(73±11) mmHg降為(59±10) mmHg (<0.05).肺血管阻力(17.8±1.9) Wood降為(13.1±1.7) Wood (<0.01);(2)6 min步行試驗從(136±40) m改善為(198±55) m (<0.01);(3)右室收縮末期內徑從(40±5) mm減為(36±6) mm (<0.05).結論波生坦可降低先心病閤併重度肺動脈高壓患者的肺動脈壓,提高患者的運動耐量,改善右室功能.
목적:관찰파생탄치료선심병합병중도폐동맥고압적림상료효.방법5례선심병합병중도폐동맥고압환자복용파생탄치료,관찰복약6월후폐동맥압、폐혈관조력、6 min보행시험、우실수축말기내경변화정황병진행통계학분석.결과복용파생탄후(1)폐동맥수축압종(96±11) mmHg강위(86±10) mmHg (<0.01),폐동맥서장압(56±10) mmHg강위(46±9) mmHg (<0.01).폐동맥평균압(73±11) mmHg강위(59±10) mmHg (<0.05).폐혈관조력(17.8±1.9) Wood강위(13.1±1.7) Wood (<0.01);(2)6 min보행시험종(136±40) m개선위(198±55) m (<0.01);(3)우실수축말기내경종(40±5) mm감위(36±6) mm (<0.05).결론파생탄가강저선심병합병중도폐동맥고압환자적폐동맥압,제고환자적운동내량,개선우실공능.
Objective To observe the clinical efficacy of bosentan in treatment of severe pulmonary hypertension related to congenital heart disease (CHD-PAH) .Methods 5 patients with severe CHD-PAH patients received bosentan therapy, then pulmonary artery pressure, pulmonary vascular resistance (PVR), 6min walk test,right ventricular end-systolic diameter (RVSD) changes were observed and statistically analyzed after six months medication. Results Pulmonary arterial systolic pressure (sPAP) was significanfly decreased from (96±11) mmHg to (86±10) mmHg, <0.01.pulmonary arterial diastolic pressure (dPAP) was significanfly decreased from (56±10) mmHg to (46±9) mmHg ( <0.01),pulmonary arterial mean pressure (mPAP) was significanfly decreased from (73 ±11) mmHg to (59 ±10) mmHg ( <0.05), pulmonary vascular resistance was significanfly decreased from (17.8±1.9) Wood to (13.1±1.7) Wood (<0.01) . 6min walk test was improved from (136±40) m to (198±55) m, <0.01.right ventricular end-systolic diameter significanfly decreased from (40±5) mm to (36±6) mm after 6 months therapy ( <0.05) . Conclusion Bosentan can decrease pulmonary arterial systolic pressure, improve exercise tolerance, improve right ventricular function in patients with severe CHD-PAH.